<DOC> 
<DOCNO>1040227_business_story_2942869.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Friday, February 27, 2004 				 Biocon joins the bandwagon 
																								Bangalore, Feb. 26 (PTI): Biocon Ltd is set to become the countrys first biotech company to be listed on the stock exchanges. The Bangalore-based biotech major today kicked off a roadshow for its initial public offering (IPO) that opens on March 11.																								The IPO, which closes on March 18, will be 100 per cent book-built and its proceeds will be used for setting up new facilities to augment submerged fermentation and chemical synthesis capacity, Biocon chairman and managing director Kiran Mazumdar-Shaw told a news conference.																								The IPO comprises fresh issue of an aggregate of 10 million equity shares of the face value of Rs 5 each in a price band of Rs 270-315 per share. 																								The offer would constitute 10 per cent of the fully diluted post-issue paid-up capital of the company. The post-issue paid-up capital of Biocon would be Rs 100 crore.																								The countrys largest biotech company clocked a revenue of Rs 372.45 crore for the nine months ended December 31, 2003 as against Rs 255.22 crore reported in the corresponding previous period. Net profit during the period under review rose to Rs 86.11 crore compared with Rs 35.31 crore in the year-ago period.																								Besides key Indian cities such as Mumbai and Ahmedabad, the company has organised roadshows in London, Singapore and Hong Kong.																								Referring to the 25-year-old companys dependence on statins  the portfolio of statins contribute to over half of its consolidated income  Mazumdar-Shaw said Biocons focus on statins will be short-term. As other products kick-in, dependence on statins will be reduced, he added.																								The chairman said that the company plans to enter the domestic market for recombinant human insulin with its own branded formulation this year Insugen  its first branded pharmaceutical product. 																								Biocon is developing a sales and marketing infrastructure to sell its brand of formulations, including insulin, in the country. 
</TEXT> 
</DOC>